Neural Cloud Enters Distribution Agreement with Intelimed to Expand into Latin America
Rhea-AI Summary
AIML (OTCQB:AIMLF) said its subsidiary Neural Cloud entered a distribution agreement with Chile-based Intelimed on Feb 18, 2026 to commercialize MaxYield™, CardioYield™, and Insight360™ across Latin America. Intelimed is exclusive in Chile and non-exclusive elsewhere, targeting hospitals, clinics, OEMs, telemedicine providers and research institutions.
The partnership aims to expand access to AI-driven cardiac software, leveraging Intelimed's regional engagements and platform that aggregates FDA- and CE-authorized diagnostic tools.
Positive
- Exclusive distribution in Chile effective Feb 18, 2026
- Non-exclusive distribution across Latin America expands commercialization reach
- Target channels: hospitals, clinics, OEMs, telemedicine providers, research institutions
Negative
- Exclusivity limited to Chile, non-exclusive elsewhere may reduce regional competitive advantage
- Commercial outcomes unspecified: no disclosed revenue or contract value in the agreement
News Market Reaction – AIMLF
On the day this news was published, AIMLF declined 0.71%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Intelimed Appointed Exclusive Distributor in Chile and Non-Exclusive Distributor Across Latin America to lead commercialization in the region
TORONTO, ON / ACCESS Newswire / February 24, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that on February 18th, 2026 its wholly owned subsidiary, Neural Cloud Solutions Inc. ("Neural Cloud"), entered into a distribution agreement with Intelimed.ai SpA ("Intelimed"), a Chile-based digital health solutions provider, to commercialize Neural Cloud's MaxYield™, CardioYield™, and Insight 360™ platforms in Latin America.
Under the terms of the agreement, Intelimed has been appointed as exclusive distributor in Chile, and non-exclusive distributor throughout the rest of Latin America for Neural Cloud's cardiac software solutions. Intelimed will focus on distributing Neural Cloud's products to hospitals, clinics, diagnostic providers, OEMs, telemedicine providers, and research institutions, in accordance with applicable regulations.
Neural Cloud's MaxYield™, CardioYield™, and Insight360™ platforms are designed to deliver advanced ECG signal enhancement, automated waveform identification, and scalable clinical reporting solutions-enabling healthcare providers to improve diagnostic accuracy, efficiency, and accessibility.
"This partnership represents an important step in expanding access to our AI-driven cardiac solutions in Latin America," said Paul Duffy, Executive Chairman and CEO of AIML Innovations. "Chile serves as a strategic anchor market, and Intelimed's presence across the broader region provides a strong foundation for sustainable growth."
Founded in 2023, Intelimed is a Chilean company which builds infrastructure that enables clinical AI to scale across fragmented healthcare systems.
Intelimed works with healthcare institutions and has active engagements across Latin American markets. Its platform aggregates advanced imaging and AI diagnostic tools from multiple global providers-often described as a "Spotify of diagnostic imaging Software as a Medical Device"-allowing clinicians to access FDA- and CE-authorized solutions through a unified adoption process.
Alan Nudman, co-founder and CEO of Intelimed, commented: "Our mission is to make high-quality digital health technologies accessible across Latin America, adapted to the realities of our healthcare systems. Neural Cloud's cardiac AI platforms align perfectly with that vision, and we are excited to introduce these solutions to clinicians seeking more efficient and accurate cardiac diagnostics."
Latin America represents a significant opportunity for digital transformation in healthcare, with increasing demand for scalable, cost-effective diagnostic technologies. Through this partnership, Neural Cloud and Intelimed aim to deliver advanced cardiac software solutions that support local clinical workflows while maintaining international standards.
About AIML Innovations Inc.
AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.
AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).
For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.
Contact:
Blake Fallis (778) 405-0882
On behalf of the Board of Directors:
Paul Duffy, Executive Chairman and CEO
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including risks associated with the implementation of the Company's products and services. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including with respect to the nature and timing of future operations and the receipt of all applicable regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.
SOURCE: AI/ML Innovations Inc.
View the original press release on ACCESS Newswire
FAQ
What did AIML (AIMLF) announce on Feb 18, 2026 about Latin America distribution?
Which Neural Cloud products will Intelimed distribute in Latin America for AIMLF?
How does the AIMLF–Intelimed deal affect clinical access in Chile and Latin America?
Will AIMLF's Neural Cloud solutions meet regulatory standards in Latin America via Intelimed?
What channels will Intelimed target to sell AIMLF's Neural Cloud platforms?
